Kiniksa Pharmaceuticals International (KNSA) Financial Statements & Analysis

Kiniksa Pharmaceuticals International (KNSA) Income Statement

Kiniksa Pharmaceuticals International reported revenue of $677.56M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 60.1% from $423.24M a year earlier. Net income was $59.01M, a net margin of 8.7%. Gross margin was 88.5% and operating margin 11.4%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $243.60M, up 55.4% from the same quarter a year earlier.

Kiniksa Pharmaceuticals International Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Kiniksa Pharmaceuticals International, plc income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	677.56	423.24	270.26	220.18	38.54	0.00	0.00	0.00	0.00
Cost of Revenue	307.22	189.22	56.52	22.90	9.10	3.81	3.28	0.29	0.03
Gross Profit	599.89	362.33	213.74	197.29	29.44	-3.81	-3.28	-0.29	-0.03
Operating Expenses
Research & Development	96.85	111.62	76.10	65.49	99.30	112.04	132.93	86.60	56.36
Selling, General & Administrative	196.27	168.01	129.43	97.95	85.95	45.32	33.75	21.56	9.04
Operating Expenses	522.67	407.95	238.93	187.51	186.08	157.36	166.68	108.16	65.40
Operating Income	77.22	-45.62	-25.20	9.77	-156.64	-157.36	-169.96	-108.16	-65.40
Other Income/Expense
Interest Income	11.65	9.46	8.54	1.25	0.10	1.13	6.05	4.72	0.53
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	11.65	9.46	8.54	1.25	0.10	1.13	6.05	4.72	0.53
Income
Income Before Tax	88.87	-36.15	-16.65	11.03	-156.54	-156.23	-163.91	-103.44	-64.87
Income Tax Expense	29.86	7.04	-30.74	-172.34	1.39	5.15	-2.05	-0.21	0.00
Net Income	59.01	-43.19	14.08	183.36	-157.92	-161.38	-161.87	-103.23	-64.87
Net Income - Continuous Operations	59.01	-43.19	14.08	183.36	-157.92	-161.38	-161.87	-103.23	-64.87
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	78.78	-43.92	-14.31	12.18	-154.18	-154.96	-160.64	-107.87	-65.37
EBIT	77.22	-45.62	-25.20	9.77	-156.64	-157.36	-	-	-
Depreciation & Amortization	1.55	1.70	2.34	2.40	2.36	2.41	3.28	0.29	0.03
Earnings Per Share
Basic EPS	1.00	-1.00	-	3.00	-2.00	-3.00	-3.00	-3.00	-2.00
Diluted EPS	1.00	-1.00	-	3.00	-2.00	-3.00	-3.00	-3.00	-2.00
Basic Shares Outstanding	74.20	71.42	70.06	69.38	68.58	61.84	54.05	29.55	32.47
Diluted Shares Outstanding	78.98	71.42	71.92	70.42	68.58	61.84	54.05	29.55	32.47

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Kiniksa Pharmaceuticals International Financial Statements

What was Kiniksa Pharmaceuticals International's revenue in fiscal 2025?

Kiniksa Pharmaceuticals International reported revenue of $677.56M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 60.1% from $423.24M a year earlier.

Is Kiniksa Pharmaceuticals International profitable?

Yes. Kiniksa Pharmaceuticals International earned net income of $59.01M in fiscal 2025, a net margin of 8.7%. In fiscal 2024 it lost $43.19M.

What is Kiniksa Pharmaceuticals International's operating margin?

Kiniksa Pharmaceuticals International's operating income was $77.22M on revenue of $677.56M in fiscal 2025, an operating margin of 11.4%, compared with -10.8% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition